Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Sylvia Haas, MD, Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, MD, PhD, Bengt Eriksson, MD, PhD, Kai Vogtlaender, Dagmar Kubitza, MD, Wolfgang Mueck, PhD, Michael Gent, DSc, Frank Misselwitz, MD, Scott D Berkowitz, MD, FACP

Blood (2009) 114 (22): 2099.

https://doi.org/10.1182/blood.V114.22.2099.2099

Published: 2009

Journal Articles

Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4

Alexander GG Turpie, MD, Kenneth A. Bauer, MD, Bruce Davidson, MD, Michael Gent, MD, Louis Kwong, MD, Michael Rud Lassen, MD, Fred Cushner, MD, Paul Lotke, MD, Scott D. Berkowitz, MD, FACP, Tiemo Joerg Bandel, Frank Misselwitz, MD, William Fisher, MD

Blood (2008) 112 (11): 35.

https://doi.org/10.1182/blood.V112.11.35.35

Published: 2008

Journal Articles

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding

Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, PhD, Bengt Eriksson, MD, PhD, Frank Misselwitz, MD, Tiemo Joerg Bandel, MD, Martin Homering, Torsten Westermeier, PhD, Michael Gent, DSc

Blood (2008) 112 (11): 36.

https://doi.org/10.1182/blood.V112.11.36.36

Published: 2008

Journal Articles

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.

Bengt Eriksson, MD, Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, PhD, Frank Misselwitz, MD, Tiemo Joerg Bandel, Martin Homering, Torsten Westermeier, Michael Gent, MD

Blood (2008) 112 (11): 1986.

https://doi.org/10.1182/blood.V112.11.1986.1986

Published: 2008

Journal Articles

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study

Harry R. Buller, Anthonie W. A. Lensing, Martin H. Prins, Giancarlo Agnelli, Alexander Cohen, Alexander S. Gallus, Frank Misselwitz, Gary Raskob, Sebastian Schellong, Annelise Segers

Blood (2008) 112 (6): 2242–2247.

https://doi.org/10.1182/blood-2008-05-160143

Published: 2008

Includes: Supplemental data

Journal Articles

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.

Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Richard J. Friedman, MD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Tiemo J. Bandel, MD, Eva Muehlhofer, MD, Frank Misselwitz, MD, William Geerts, MD

Blood (2007) 110 (11): 6.

https://doi.org/10.1182/blood.V110.11.6.6

Published: 2007

Journal Articles

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

Ajay K. Kakkar, MD, PhD, Benjamin Brenner, MD, Ola E. Dahl, MD, PhD, Bengt I. Eriksson, MD, PhD, Patrick Mouret, MD, Jim Muntz, MD, Tiemo J. Bandel, MD, Frank Misselwitz, MD, PhD, Sylvia Haas, MD

Blood (2007) 110 (11): 307.

https://doi.org/10.1182/blood.V110.11.307.307

Published: 2007

Journal Articles

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.

Michael R. Lassen, MD, Alexander G.G. Turpie, MD, Nadia Rosencher, MD, Lars C. Borris, MD, Walter Ageno, MD, Jay R. Lieberman, MD, Tiemo J. Bandel, MD, Frank Misselwitz, MD, PhD

Blood (2007) 110 (11): 308.

https://doi.org/10.1182/blood.V110.11.308.308

Published: 2007

Journal Articles

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Wolfgang Mueck, PhD, Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Eva Muehlhofer, PhD, Frank Misselwitz, MD, PhD

Blood (2006) 108 (11): 903.

https://doi.org/10.1182/blood.V108.11.903.903

Published: 2006

Journal Articles

VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.

Sebastian M. Schellong, MD, Jan Beyer, MD, Kai Halbritter, MD, Benjamin Schmidt, MD, Alexander G.G. Turpie, MD, Bengt I. Eriksson, MD, PhD, Frank Misselwitz, MD, PhD, Peter Kälebo, MD

Blood (2005) 106 (11): 281.

https://doi.org/10.1182/blood.V106.11.281.281

Published: 2005

Journal Articles

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Alexander G.G. Turpie, MD, Kenneth Alan Bauer, MD, Lars Borris, MD, Ola E. Dahl, MD, PhD, William D. Fisher, MD, Michael Gent, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Louis M. Kwong, MD, Martin Homering, PhD, Frank Misselwitz, MD, PhD, Bengt I. Eriksson, MD, PhD

Blood (2005) 106 (11): 277.

https://doi.org/10.1182/blood.V106.11.277.277

Published: 2005

Journal Articles

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Bengt I. Eriksson, MD, PhD, Lars Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Frank Misselwitz, MD, PhD, Eva Muehlhofer, PhD, Peter Kälebo, MD, PhD

Blood (2005) 106 (11): 280.

https://doi.org/10.1182/blood.V106.11.280.280

Published: 2005

Journal Articles

The Oral, Direct Factor Xa Inhibitor BAY 59-7939 Does Not Cross-React with Anti-Heparin/PF4 (Heparin-Induced Thrombocytopenia) Antibodies.

Jeanine M. Walenga, PhD, Debra Hoppensteadt, PhD, Omer Iqbal, MD, Brian Neville, PhD, Walter P. Jeske, PhD, Margaret Prechel, PhD, Harry L. Messmore, PhD, Frank Misselwitz, MD, PhD, Mamdouh Bakhos, PhD

Blood (2005) 106 (11): 1883.

https://doi.org/10.1182/blood.V106.11.1883.1883

Published: 2005

NARROW

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

The Oral, Direct Factor Xa Inhibitor BAY 59-7939 Does Not Cross-React with Anti-Heparin/PF4 (Heparin-Induced Thrombocytopenia) Antibodies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only